Amarin Corp PLC News - AMRN

Get an advanced news scanner tailored to your needs by ADVFN

Enhance your trading experience

Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024

DUBLIN, Ireland and BRIDGEWATER, N.J., April 15, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc...

Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24

DUBLIN, Ireland and BRIDGEWATER, N.J., April 08, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc...

New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups

New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups Canada...

New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups

-- Findings Presented on VASCEPA/VAZKEPA Utility in REDUCE-IT Patient Subgroups by Baseline High/Low Lp(a...

Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe

DUBLIN, Ireland and BRIDGEWATER, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc...

Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo

-- Subgroup Analyses from REDUCE-IT® and Mechanistic Data on Icosapent Ethyl(IPE)/Eicosapentaenoic Acid (EPA...

Form ARS - Annual Report to Security Holders

Form DEF 14A - Other definitive proxy statements

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form 8-K - Current report

Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

-- Company Delivers Total Revenues of $75 Million in the Fourth Quarter and $306 Million for the Full-Year 2023...

Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024

DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN...

Form PRE 14A - Other preliminary proxy statements

Form 4 - Statement of changes in beneficial ownership of securities

Number sleven 22 minutes ago

RMB, Icosapent ethyl is an ethyl ester of EPA. EPA is a molecule that is naturally produced. Icosapent ethyl requires a bit of chemistry. This distinction was part of our complaint to the ITC. Any ethyl ester should not be considered a dietary supplement. They are actually unapproved drugs. Google ethyl ester. That should explain the process for you.
Sleven,

👍️0

rosemountbomber 1 hour ago

What is the difference in either molecular formula or chemical structure between EPA and "active" EPA?

👍️0

Birdbrain Ideas 2 hours ago

I remember your 2022 post and how you seemed rather rudely treated until you got into the room. Thanks for going to the meeting again and I hope this time that they welcome you and give you food and gifts, because you really do represent us all. If you can get any sense of when the company can begin buying back shares, please let us all know. I would be surprised if the share price does not begin a steady rise once the buyback starts. And by steady rise, I mean a couple cents a day, which probably all of us would embrace after what has seemed like a long dark winter.

👍️ 1

Birdbrain Ideas 2 hours ago

Your measured response to my rude adjective was just another example of your higher intelligence. I see what you say about the fallacy of calling Vascepa fish oil in any form. And Amarin goes out of its way, I think, to generally avoid bringing fish into the equation.

But I think the point I was making was that you can do a lot of funny things with advertising and promotions in general with fish whereas I can't think of anything you can do to promote a drug whose name nobody can pronounce whether we call it Icosapent ethyl or Vascepa. You'd think just saying that it can reduce the chance of heart attacks or strokes by over 25 percent would leave an impression on most doctors, but apparently not.

I guess my question is whether fish is indeed a necessary ingredient in the creation of Vascepa. Dr. Bhatt seemed to be saying that Vascepa cannot be made without EPA from fish because algae and other plant-based ingredients rather than fish haven't worked yet. If so, then I think Amarin would be fully within its rights to use fish to promote itself. And this would seem to be an easy sell because just about everybody seems to agree that fish are good for us and that people who live in areas where they mainly just eat fish and vegetables live longer and healthier than we do. And since the massive fish oil supplement industry has convinced so many people that supplements are great for all kinds of reasons, Amarin could steal a move from the supplements playbook and take over their market by convincing people and their doctors that Amarin is the 100-pound gorilla and Vascepa is the only product they should consider using.

👍️0

Number sleven 3 hours ago

Luck, Infringement is part of the generic business model. That's why the lawyer, representing Hikma, was so concerned about the downstream effect of this case moving past the pleading phase. The Hatch Waxman act was poorly drafted and implemented. Since it's introduction in 1984, (from memory) section 8 has given these companies free reign to infringe on valid method of use patents. GSK v Teva opened a door. If the federal circuit remands this case, we should all read the wording carefully.
Sleven,

👍️0

rosemountbomber 3 hours ago

One or the other.

👍️0

L0tsaluck2000 3 hours ago

I recall when Hikma first talked about their generic, they referenced the potential market size by using the full projections of Vasepa sales potential, not just the share of the market that was high trigs. They were either intending to infringe or intentionally misleading their shareholders and the media.

👍️0

liamlinden 3 hours ago

DMC8.I read most of the history of Amrn V Hikma and it dates back to 2010 /2012 and they went at it in 2016 and I know Amrn gave Teva a million to stay away for a few years but it reads to me that Amrn have no chance winning the skinny labeling [infrigment or anything else in the future .Who knew when we all became millionaires DEC13th that it allowed Hikma to go after the TG Patients,what a fcuking mess.I wish you had not posted that DM lol my head is fried and i just read 70% of it.

👍️0

CaptBeer 3 hours ago

I remember you telling us this story. I hope they treat you better this time.

👍️0

rosemountbomber 5 hours ago

Have a safe trip.

👍️ 1

liamlinden 6 hours ago

Hi Capt.I am going to the AGM tomorrow and its in the same Building when I was at the 2022 meeting .It took me an hour to finally get into the room .The lobby told me no meeting then put me on an elevator with no buttons to press then left in a room for 30 minutes then interviewed by an amarin guy who told me I had no shares in Amarin lol.I finally got into the room and luckily a few directors knew me so CEO came down after and thanked me for coming lol..I was the only sharehoilder at the table and and 6 zoom screens ,Anyway its 8.30 in Galway and driving up at 4 am so hitting the nest soon

👍️ 8

Number sleven 6 hours ago

https://fedcircuitblog.com/other-cases/amarin-pharma-inc-v-hikma-pharmaceuticals-usa-inc/
Sleven,

👍️0

Number sleven 6 hours ago

https://bjcardio.co.uk/2023/05/icosapent-ethyl-use-in-clinical-practice-current-and-future-directions/
Sleven,

👍️0

Number sleven 6 hours ago

https://www.sciencedirect.com/science/article/pii/S175646462400166X
Sleven,

👍️0

ORBAPU 7 hours ago

I’m a renaissance man.

👍️0

FlyFishingStocks 7 hours ago

a pompous, arrogant engineer and a psychotherapist?

FlyFishingStocks 7 hours ago

hmmm.... pompous, arrogant engineers who are well versed in mathematics (but fail to appreciate the value of a down trendline) are smarter and know more than Dr. Bhatt!?

Saying V is not derived from fish is tantamount to saying your integument is not derived from skin. LOL

👍️0

hayward 9 hours ago

DMC*

Does that effect us ? TIA

Michael

👍️0

DMC8 9 hours ago

$20.7m notional buy order filled.

👍️0

DMC8 10 hours ago

Academia's reflection on AMARIN-HIKMA litigation.
https://jipel.law.nyu.edu/pharmaceutical-patent-two-step-the-adverse-advent-of-amarin-v-hikma-type-litigation/

👍️ 1

DMC8 10 hours ago

👍️0

CaptBeer 10 hours ago

No Matter how you say it!

👍️ 2

CaptBeer 10 hours ago

FYI, here's a summary of REDUCE-IT Subgroup Analysis including the new REDUCE-IT Lp(a):
The pleiotropic effects of VASCEPA are truly amazing. What's the key? It's the EPA Stupid!

👍️ 6

seve333 11 hours ago

Driving the stock down to .50 cents would be insane. Nobody knows what Denner's master plan is but the buyback in really the only catalyst right now I can see to get this over a buck. We have not been over 1.40 in a very long time so to get over that no ideas what it will take but hopefuly somethign other than waiting on europe sales.

👍️0

seve333 11 hours ago

I highly doubt it there is no way the buyback would be voted down it relly all we go to raise the stock price right now. It is just AMRN doing waht AMRN does.

👍️0

Birdbrain Ideas 11 hours ago

It looks like ChatGPT was hallucinating a little bit when it answered your second question. Yes, the trial-level judge who originally dismissed the case against Hikma can dismiss the lawsuit again, but only after both sides have the chance to gather and exchange evidence, including emails and correspondence that Amarin will hope contains a smoking gun or two that will further illustrate Hikma's bad intentions. At a later point prior to trial, Hikma will again move for dismissal of the lawsuit on the grounds that the judge can find as a matter of law that Amarin cannot satisfy the legal points necessary to take the case to a jury. And, at that stage, the rules of the game will not be as favorable to Amarin as they were at the current stage, when the trial judge was supposed to accept that everything in the lawsuit was true.

ChatGPT makes it sound like the judge can respond to the appeals reversal of his dismissal by merely writing the equivalent of a legal essay back to the appeals court to better explain why he threw out the case in a way that he thinks the appeals judges might accept.

With a reversal, three judges on the Federal Circuit (assuming its a unanimous ruling, which it certainly seemed it will be based on the tone of the arguments) will be telling the trial judge that he was wrong. The judge cannot then merely "choose to reaffirm its dismissal of the case" if he "believes that its original decision was correct." That's where ChatGPT was hallucinating.

Judges don't argue with each other that way. It's very much like the military. The lower court judge will be told politely by a superior (the Federal Circuit) that he is wrong. If he tried to protest and insist he was right, the higher court would take the gloves off and scold him like a small child. And he'd lose the respect of his fellow judges. I've been watching courts closely for nearly 50 years. This would never happen!

👍️ 1

Number sleven 11 hours ago

Chromosome,
https://www.uscourts.gov/about-federal-courts/court-role-and-structure/about-us-courts-appeals
Sleven,

👍️0

CaptBeer 11 hours ago

CVD is the #1 Killer worldwide!
Here's some interesting Stats for some of the countries in which VASCEPA/VAZKEPA is being sought for prescriptions:

👍️ 1

Chromosome 11 hours ago

Thank you NS.

👍️0

Number sleven 11 hours ago

Chromosome, The district court made a ruling. We appealed that ruling. The court of appeals will have final say. If they remand this back to the lower court, the motion to dismiss would no longer be something for the district court to consider. The lawsuit would move forward.
Sleven,

👍️0

Chromosome 11 hours ago

Thank you Captain…I wonder how much wounded pride at having the appellate court remand the case back to you plays into actually reversing their original decision vs. finding a justification for holding their ground. I tried search for some statistics on that but could not identify any reliable numbers although I’ll keep digging. Thanks again.

👍️0

Denisk 12 hours ago

No idea. But I do see that the XBI went down 10% over the past month.

👍️0

north40000 12 hours ago

Shares of Amarin are currently trading at an unjustified low value. Has there been a leak of results of proxy votes submitted on April 12 due date?

👍️0

DMC8 12 hours ago

In addition, AMRN is the first to discover IPE potential medical benefits, spent millions into clinically researches, and put IPE into clinical trial, which eventually led proven medical benefits of IPE (Vascepa), and was awarded the patents.

Seriously, how did judge Du brush it off lightly that Vascepa’s patents were common knowledge seriously is very mind-boggling.

👍️ 1

north40000 13 hours ago

I agree—icosapent ethyl is not found in fish, but was manufactured/synthesized in a laboratory by its inventors.

👍️0

CaptBeer 17 hours ago

My Question to ChatGPT: When a lower US Federal court dismisses a case and the Appeals Court reverses that decision, what happens next?

Answer: When a lower US Federal court dismisses a case and the Appeals Court reverses that decision, the case is typically remanded back to the lower court for further proceedings. The lower court must then reconsider the case in light of the Appeals Court's ruling and potentially take additional steps, such as holding a trial or further hearings, to resolve the matter.

Further Question: Can the lower court come to their previous decision to dismiss?

Answer: Yes, the lower court can still come to its previous decision to dismiss the case, even after the Appeals Court has reversed its decision. However, the lower court must base its decision on the legal principles and guidance provided by the Appeals Court's ruling. If the lower court believes that its original decision was correct in light of the Appeals Court's guidance, it may choose to reaffirm its dismissal of the case.

👍️ 1

Chromosome 21 hours ago

“Previous conclusion”

👍️0

Chromosome 21 hours ago

Thanks NS. Do you know if once remanded back to the district court, the expectation is for the district court to reverse its original decision to dismiss or can they come to their precious conclusion. Thanks in advance.

👍️0

DMC8 21 hours ago

Please be reminded below are hard facts and financial numbers. (Not some 50cts BS lie propagated)

👍️0

DMC8 22 hours ago

CEO and Sarissa have bought between 73cts to $1.06 in the most recent 6 months, and also constantly reiterated that the share price is grossly undervalued. Given this, I do not think Sarissa’s plan is to tank the share price to 50cts and buyback.

I only believed in what Sarissa/CEO do and what they said are synchronized, and not by some forumers (possibly shorts/bashers) saying 50cts is Sarissa’s plan for share buyback (absolute BS).

👍️0

Number sleven 22 hours ago

RMB, The appeals court can vacate the order to dismiss. It looks like that is what they are going to do. The case is then remanded back to the district court. The ruling to dismiss at the pleading phase didn't go over well with the panel. This case should go back to the district court. Discovery schedule should then be set. It will be as if the dismissal never happened. It's not official until the ruling is issued. I still think it's likely. If you want I can post a link to the arguments. I have listened to it several times. I really enjoyed the part where the chief judge thrashes the Hikma attorney.
Sleven,

👍️ 1

rosemountbomber 23 hours ago

Thanks Sleven. I realize what remand means. It could mean a new trial, new sentencing hearing/order, a correction of the trial court’s order or other actions. I guess where I was confused is that it sounds like the Appeals Court cannot simply reverse the lower court's decision and rule for the other party.

👍️0

Nukemtiltheyglow 23 hours ago

Tilapia is a cichlids, Carp are ciphrinids? not related to Tilapia. Both are pretty good to eat. Their meat is white.

👍️0

ORBAPU 24 hours ago

You pretty much nailed it.

👍️0

Number sleven 1 day ago

RMB, Remanding the case back to the district court is reversing the decision of the lower court. The appeal was over the ruling to dismiss. Listen to the arguments. Two of the three judges where fairly clear about their leaning.
Sleven,

👍️0

rosemountbomber 1 day ago

What I was referring to is that there is very small chance that the Appellate court reverses the lower court decision. But barring that remanding back is the next best thing. We get another bite at the apple

👍️0

Mr Stockboy 1 day ago

Myself not being a chemist but once working for a chemist the following HIT ME LIKE A TON OF BRICKS.

Quote from ORBAPU: "Icosapent ethyl or ethyl eicosapentaenoic acid is a synthetic derivative of the omega-3 fatty acid eicosapentaenoic acid (EPA)"... in another post he/she wrote "IPE does not occur in nature"... earlier he/she posted on the chemistry.

I AM EMBARRASSED AT MY OWN IGNORANCE!

I am equally embarrassed no one schooled Amarin's lawyers (in the past before Judge Du), the case before her was NOT OVER EPA, BUT IPE!!!! Do any of you lawyers see what I'm saying? IPE, not EPA, was the invention protected by the patents!!! I am so blown away right now, by this revelation.

The opposition before Du focused on an EPA argument, and Amarin's uninformed non-chemist lawyers fell right into the trap. "JUDGE DU!" Amarin's lawyer should have shouted, "This case IS NOT ABOUT EPA, it's about Amarin's IPE invention! Judge Du, the opposition presents articles all focused on EPA, not IPE! Fish are not swimming about with IPE in them!"

Now there are a lot smarter people than me on IHUB, so what do you think? If I were hence promoting Vascepa/Vazkepa my slogan would read: "It's NOT old smelly fish oil EPA, it's IPE, a synthetic invention of Amarin not found in nature."

Feedback?

👍️0

Number sleven 1 day ago

RMB, I'm not sure I understand what you mean.
Sleven,

👍️0

rosemountbomber 1 day ago

Sleven, not as good as an outright overturn but a lot better than where we stand.

👍️0

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Amarin Corp PLC (AMRN)

Get an advanced news scanner tailored to your needs by ADVFN

AMRN News

Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024

Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24

New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups

New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups

Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe

Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo

Form ARS - Annual Report to Security Holders

Form DEF 14A - Other definitive proxy statements

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form 8-K - Current report

Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024

Form PRE 14A - Other preliminary proxy statements

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

AMRN Discussion

Your Recent History

Company

Business

Popular

Get The App

Trending Now

Toplists

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Amarin Corp PLC (AMRN) News

Amarin Corp PLC (AMRN)

Get an advanced news scanner tailored to your needs by ADVFN

AMRN News

Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024

Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24

New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups

New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups

Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe

Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo

Form ARS - Annual Report to Security Holders

Form DEF 14A - Other definitive proxy statements

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form 8-K - Current report

Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024

Form PRE 14A - Other preliminary proxy statements

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

AMRN Discussion

Your Recent History

Company

Business

Popular

Get The App